切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2021, Vol. 17 ›› Issue (06) : 650 -656. doi: 10.3877/cma.j.issn.1673-5250.2021.06.005

专题论坛

组织因子途径抑制物与妊娠相关疾病的研究现状
李冰1,1, 徐婷婷2,2, 朱丽丽1,1, 李宁2,2, 徐爱群3,3, 张俊2,2, 李淑红2,†,2()   
  • 收稿日期:2021-03-04 修回日期:2021-10-28 出版日期:2021-12-01
  • 通信作者: 李淑红

Current situation of relationship between tissue factor pathway inhibitor and pregnancy-related diseases

Bing Li1,1, Tingting Xu2,2, Lili Zhu1,1, Ning Li2,2, Aiqun Xu3,3, Jun Zhang2,2, Shuhong Li2,2,†()   

  • Received:2021-03-04 Revised:2021-10-28 Published:2021-12-01
  • Corresponding author: Shuhong Li
  • Supported by:
    Key Laboratory Project of Fertility Control Technology of National Health and Family Planning Commission(2018KF005); National Natural Science Foundation of China for Youths(81701453); Yantai Science and Technology Plan Project(2020YD001)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李冰, 徐婷婷, 朱丽丽, 李宁, 徐爱群, 张俊, 李淑红. 组织因子途径抑制物与妊娠相关疾病的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(06): 650-656.

Bing Li, Tingting Xu, Lili Zhu, Ning Li, Aiqun Xu, Jun Zhang, Shuhong Li. Current situation of relationship between tissue factor pathway inhibitor and pregnancy-related diseases[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(06): 650-656.

组织因子途径抑制物(TFPI)是人体血浆中的一种大分子质量蛋白质。人TFPI可被分为TFPI-1、-2亚型。人TFPI广泛表达于人体细胞中，参与机体凝血过程。目前研究发现，TFPI表达水平在心血管疾病，妊娠相关疾病，如子痫前期(PE)，溶血、肝酶升高和低血小板计数(HELLP)综合征，羊水栓塞(AFE)，血液病，脓毒症，以及肿瘤的发生、发展中起着重要作用。笔者拟就人TFPI的2种亚型的基本特征，人TFPI-1亚型及其分布、抑制机体凝血功能机制及其与妊娠相关疾病关系，以及人TFPI-2亚型分布、与妊娠相关疾病关系的最新研究现状进行阐述，旨在为人TFPI在妊娠相关疾病的诊断及基因治疗，提供新思路、新策略。

关键词: 凝血致活酶, 组织因子途径抑制物，人, 妊娠并发症, 分子靶向治疗, 弥漫性血管内凝血, 先兆子痫, 栓塞，羊水

Tissue factor pathway inhibitor (TFPI) is a high molecular weight protein in human plasma. TFPI is divided into TFPI-1 and TFPI-2 subtypes. TFPI is widely expressed in human cells and participates in the process of blood coagulation. Nowadays, studies have found that expression of TFPI plays an important role in the occurrence and development of heart disease, various pregnancy-related diseases, such as preeclampsia (PE), hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome, amniotic fluid embolism (AFE), hematopathy, sepsis, and tumor. The author intends to elaborate on basic characteristics of human TFPI-1 and TFPI-2 subtypes, distribution of human TFPI-1 subtype, mechanism of inhibiting blood coagulation, and its relationship with pregnancy-related diseases, and latest research status of distribution of human TFPI-2 subtype and its relationship with pregnancy-related diseases, in order to provide new ideas and strategies for diagnosis and gene therapy of TFPI in pregnancy-related diseases.

Key words: Thromboplastin, Tissue factor pathway inhibitor, human, Pregnancy complications, Molecular targeted therapy, Disseminated intravascular coagulation, Pre-eclampsia, Embolism, amniotic fluid
[1]
Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia[J]. Int J Hematol, 2020, 111(1): 42-50. DOI: 10.1007/s12185-018-2548-6.
[2]
Grover SP, Mackman N. Tissue factor in atherosclerosis and atherothrombosis[J]. Atherosclerosis, 2020, 307: 80-86. DOI: 10.1016/j.atherosclerosis.2020.06.003.
[3]
Wood JP, Ellery PE, Maroney SA, et al. Biology of tissue factor pathway inhibitor[J]. Blood, 2014, 123(19): 2934-2943. DOI: 10.1182/blood-2013-11-512764.
[4]
Augustsson C, Svensson A, Kjaer B, et al. Factor Ⅹa and Ⅶa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain[J]. J Thromb Haemost, 2018, 16(5): 893-904. DOI: 10.1111/jth.14000.
[5]
Mehic D, Tolios A, Hofer S, et al. Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency[J]. Blood Adv, 2021, 5(2): 391-398. DOI: 10.1182/bloodadvances.2020003464.
[6]
Korte W, Graf L. The potential close future of hemophilia treatment - gene therapy, TFPI inhibition, antithrombin silencing, and mimicking factor Ⅷ with an engineered antibody[J]. Transfus Med Hemother, 2018, 45(2): 92-96. DOI: 10.1159/000488152.
[7]
Winckers K, Thomassen S, Ten Cate H, et al. Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use[J]. PLoS One, 2017, 12(2): e0168273. DOI: 10.1371/journal.pone.0168273.
[8]
Maroney SA, Ferrel JP, Collins ML, et al. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans[J]. J Thromb Haemost, 2008, 6(8): 1344-1351. DOI: 10.1111/j.1538-7836.2008.03033.x.
[9]
Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein[J]. Arterioscler Thromb Vasc Biol, 2016, 36(1): 9-14. DOI: 10.1161/ATVBAHA.115.305996.
[10]
Wood JP, Petersen HH, Yu B, et al. TFPIα interacts with FⅤa and FⅩa to inhibit prothrombinase during the initiation of coagulation[J]. Blood Adv, 2017, 1(27): 2692-2702. DOI: 10.1182/bloodadvances.2017011098.
[11]
Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment[J]. Thromb Res, 2016, 141(Suppl 2): S28-S30. DOI: 10.1016/S0049-3848(16)30359-0.
[12]
Reglińska-Matveyev N, Andersson HM, Rezende SM, et al. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain[J]. Blood, 2014, 123(25): 3979-3987. DOI: 10.1182/blood-2014-01-551812.
[13]
Leal de Azeredo E, Solórzano VE, de Oliveira DB, et al. Increased circulating procoagulant and anticoagulant factors as TF and TFPI according to severity or infecting serotypes in human dengue infection[J]. Microbes Infect, 2017, 19(1): 62-68. DOI: 10.1016/j.micinf.2016.08.005.
[14]
Peraramelli S, Thomassen S, Heinzmann A, et al. Role of exosite binding modulators in the inhibition of FⅩa by TFPI[J]. Thromb Haemost, 2016, 115(3): 580-590. DOI: 10.1160/TH15-04-0354.
[15]
Ahnström J, Andersson HM, Hockey V, et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S[J]. Blood, 2012, 120(25): 5059-5062. DOI: 10.1182/blood-2012-05-432005.
[16]
Siebert AE, Maroney SA, Martinez ND, et al. Intrauterine lethality in TFPI gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression[J]. J Thromb Haemost, 2021, 19(6): 1483-1492. DOI: 10.1111/jth.15299.
[17]
Castillo MM, Yang Q, Zhan M, et al. Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency[J]. Blood Adv, 2019, 3(3): 489-498. DOI: 10.1182/bloodadvances.2018018853.
[18]
张华，张红英，袁宁霞，等. 正常足月产妇羊水组织因子水平与妊娠高凝状态、羊水栓塞的关系研究[J]. 检验医学与临床，2016, 16(3): 322-324. DOI: 10.3969/j.issn.1672-9455.2016.03.014.
[19]
Uszyński W, Zekanowska E, Uszyński M, et al. New observations on procoagulant properties of amniotic fluid: microparticles (MPs) and tissue factor-bearing MPs (MPs-TF), comparison with maternal blood plasma[J]. Thromb Res, 2013, 132(6): 757-760. DOI: 10.1016/j.thromres.2013.10.001.
[20]
Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis[J]. Lancet Glob Health, 2014, 2(6): e323-e333. DOI: 10.1016/S2214-109X(14)70227-X.
[21]
熊钰，楼懿婷，蔡旭，等. 子痫前期孕妇分娩前后出凝血功能动态改变[J]. 中国实用妇科与产科杂志，2013, 29(3): 200-203.
[22]
王晓丹，韩翠欣，班玲，等. 组织因子及其抑制物在妊娠期高血压疾病患者血浆中的表达及临床意义[J]. 中国计划生育和妇产科，2016, 8(8): 51-54. DOI: 10.3969/j.issn.1674-4020.2016.08.15.
[23]
Luo C, Pook E, Wang F, et al. ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease[J]. Gene, 2020, 753: 144805. DOI: 10.1016/j.gene.2020.144805.
[24]
Chen D, Xia M, Hayford C, et al. Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE-/- mice[J]. Circulation, 2015, 131(15): 1350-1360. DOI: 10.1161/CIRCULATIONAHA.114.013423.
[25]
Efthymiou M, Arachchillage DRJ, Lane PJ, et al. Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome[J]. Thrombosis Res, 2018, 170: 60-68. DOI: 10.1016/j.thromres.2018.08.003.
[26]
Fei X, Wang H, Yuan W, et al. Tissue factor pathway inhibitor-1 is a valuable marker for the prediction of deep venous thrombosis and tumor metastasis in patients with lung cancer[J]. Biomed Res Int, 2017, 2017: 8983763. DOI: 10.1155/2017/8983763.
[27]
Zhao XP, He SW, Yue B, et al. Molecular characterization, expression analysis, and bactericidal activity of the derivative peptides of TFPI-1 and TFPI-2 in half-smooth tongue sole, Cynoglossus semilaevis[J]. Fish Shellfish Immunol, 2016, 58: 563-571. DOI: 10.1016/j.fsi.2016.10.003.
[28]
He SW, Zhang J, Li NQ, et al. A TFPI-1 peptide that induces degradation of bacterial nucleic acids, and inhibits bacterial and viral infection in half-smooth tongue sole, Cynoglossus semilaevis[J]. Fish Shellfish Immunol, 2017, 60: 466-473. DOI: 10.1016/j.fsi.2016.11.029.
[29]
白英，史旭波，郭诗东. 组织因子途经抑制物基因对血管内皮细胞分泌层黏连蛋白的影响[J]. 临床荟萃，2013, 28(10): 1116-1119. DOI: 10.3969/j.issn.1004-583X.2013.10.013.
[30]
傅羽，王世鹏，胡晶，等. 腺病毒介导TFPI基因转染诱导血管平滑肌细胞凋亡机制的探讨[J]. 哈尔滨医科大学学报，2013, 47(1): 19-23. DOI: 10.3969/j.issn.1000-1905.2013.01.005.
[31]
马丹丹，李辉，傅羽，等. TFPI基因转染对血管平滑肌细胞中细胞凋亡抑制蛋白的调控[J]. 中国动脉硬化杂志，2015, 23(8): 769-773.
[32]
Fazil MHUT, Chalasani MLS, Choong YK, er al. A C-terminal peptide of TFPI-1 facilitates cytosolic delivery of nucleic acid cargo into mammalian cells[J]. Biochimica Biophys Acta Biomembr, 2020, 1862(2): 183093. DOI: 10.1016/j.bbamem.2019.183093.
[33]
Kamei S, Kazama Y, Kuijper JL, et al. Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene[J]. Biochim Biophys Acta, 2001, 1517(3): 430-435. DOI: 10.1016/s0167-4781(00)00298-0.
[34]
Wang G, Zeng Y, Chen S, et al. Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells[J]. Sci Rep, 2017, 7(1): 13575. DOI: 10.1038/s41598-017-14148-8
[35]
Egan K, O′Connor H, Kevane B, et al. Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia[J]. Thromb Haemost, 2017, 117(8): 1549-1557. DOI: 10.1160/TH16-12-0949.
[36]
Macdonald TM, Tong S, Myers J, et al. Circulating tissue factor pathway inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia[J]. Placenta, 2021, 105: 32-40. DOI: 10.1016/j.placenta.2021.01.018.
[37]
Karaszi K, Szabo S, Juhasz K, et al. Increased placental expression of placental protein 5 (PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: relevance to impaired trophoblast invasion？[J]. Placenta, 2019, 76: 30-39. DOI: 10.1016/j.placenta.2019.01.011.
[38]
Xiao X, Tao X, Wang YX, et al. Hypomethylation of tissue factor pathway inhibitor 2 in human placenta of preeclampsia[J]. Thromb Res, 2017, 152: 7-13. DOI: 10.1016/j.thromres.2017.02.005.
[39]
Zheng L, Huang J, Su Y, et al. Vitexin ameliorates preeclampsia phenotypes by inhibiting TFPI-2 and HIF-1α/VEGF in a l-NAME induced rat model[J]. Drug Dev Res, 2019, 80(8): 1120-1127. DOI: 10.1002/ddr.21596.
[40]
Zheng LL, Huang J, Su Y, et al. Overexpression of tissue factor pathway inhibitor 2 attenuates trophoblast proliferation and invasion in preeclampsia[J]. Hum Cell, 2020, 33(3): 512-520. DOI: 10.1007/s13577-020-00322-0.
[41]
Andresen MS, Stavik B, Sletten M, et al. Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells[J]. Sci Rep, 2020, 10(1): 4036. DOI: 10.1038/s41598-020-61018-x.
[42]
Cao Y, Guo C, Yin Y, et al. Lysine-specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI-2[J]. Mol Med Rep, 2018, 18(1): 733-740. DOI: 10.3892/mmr.2018.9047.
[43]
程春郁，任占军，黄丹华，等. TFPI-2对缺氧大鼠星形胶质细胞生物学特性及机制的研究[J]. 中国免疫学杂志，2019, 35(9): 1047-1052. DOI: 10.3969/j.issn.1000-484X.2019.09.005.
[44]
Dong YL, Tan QF, Tao L, et al. Hypermethylation of TFPI2 correlates with cervical cancer incidence in the Uygur and Han populations of Xinjiang, China[J]. Int J Clin Exp Pathol, 2015, 8(2): 1844-1854.
[45]
孟斐. 组织因子途径抑制物-2在宫颈癌中的表达及其对宫颈癌细胞增殖、凋亡的影响[J]. 中国老年学杂志，2015, 35(1): 52-55. DOI: 10.3969/j.issn.1005-9202.2015.01.026.
[46]
李娜，熊娇，史明媚，等. 宫颈癌组织中组织因子途径抑制物-2表达变化及其与VEGF表达、微血管密度的相关性[J]. 山东医药，2018, 58(3): 59-61. DOI: 10.3969/j.issn.1002-266X.2018.03.018.
[47]
He SW, Wang JJ, Du X, et al. A teleost TFPI-2 peptide that possesses a broad antibacterial spectrum and immune-stimulatory properties[J]. Fish Shellfish Immunol, 2018, 82: 469-475. DOI: 10.1016/j.fsi.2018.08.051.
[48]
Kasetty G, Smeds E, Holmberg E, et al. Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections[J]. BMC Microbiol, 2016, 16(1): 129. DOI: 10.1186/s12866-016-0750-3.
[49]
Zhang M, Yue B, Zhang AH, et al. TC38, a teleost TFPI-2 peptide that kills bacteria via penetration of the cell membrane and interaction with nucleic acids[J]. Fish Shellfish Immunol, 2017, 64: 104-110. DOI: 10.1016/j.fsi.2017.03.001.
[50]
Papareddy P, Kalle M, Sørensen OE, et al. The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis[J]. PLoS Pathog, 2013, 9(12): e1003803. DOI: 10.1371/journal.ppat.1003803.
[51]
Ali MN, Kasetty G, Elvén M, et al. TFPI-2 protects against gram-negative bacterial infection[J]. Front Immunol, 2018, 9: 2072. DOI: 10.3389/fimmu.2018.02072.
[1] 张蓝心, 高天琦, 徐岭植, 李曼. 激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的治疗进展[J]. 中华乳腺病杂志(电子版), 2022, 16(06): 365-369.
[2] 张军, 赵崇如, 刘强. 三阴性乳腺癌免疫治疗2021年度盘点[J]. 中华乳腺病杂志(电子版), 2022, 16(03): 133-137.
[3] 卢静璐, 吴子平, 陆劲松. 促性腺激素释放激素受体在乳腺癌中的表达与作用及其靶向药物研究进展[J]. 中华乳腺病杂志(电子版), 2022, 16(03): 179-182.
[4] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[5] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[6] 王璐, 樊杨. 子宫内膜癌相关生物标志物研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 511-516.
[7] 杨皓媛, 龚杰, 邹青伟, 阮航. 哮喘孕妇的母婴不良妊娠结局研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 522-529.
[8] 娄丽丽, 刘瀚旻. 儿童哮喘易感基因及表观遗传学研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(03): 249-255.
[9] 张晓芳, 王平. 阴道黑色素瘤诊疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(06): 621-626.
[10] 高坎坎, 钟华敏, 谢永强, 邓秋连, 高飞, 王洁琳, 龙燕. 女性泌尿生殖道支原体感染及其耐药率分析[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(05): 569-576.
[11] 徐瑜杰, 赵国栋. 晚期胃癌治疗方法的研究进展和挑战[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 451-455.
[12] 陈真, 漆洪波. 易栓症与胎儿生长受限[J]. 中华产科急救电子杂志, 2023, 12(01): 18-21.
[13] 郎虓, 程蔚蔚. 妊娠期铁缺乏与贫血[J]. 中华产科急救电子杂志, 2022, 11(04): 202-207.
[14] 王晓娜, 白桂芹. 体外膜肺氧合技术在重症孕产妇救治中的应用[J]. 中华产科急救电子杂志, 2022, 11(02): 81-87.
[15] 段红霞, 刘欣, 栗方芝, 张云起, 李瑞基, 庄金强. 羊水栓塞的诊断及治疗策略研究进展[J]. 中华诊断学电子杂志, 2023, 11(02): 133-135.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号